Impact of Hypoglycemia on Basal Insulin Discontinuation and Costs

This research article investigates the impact of hypoglycemia experienced within the first six months of basal insulin initiation on treatment discontinuation, healthcare resource use, and associated costs in patients with type 2 diabetes (T2D) in the United States. Using a retrospective cohort study design, researchers analyzed data from the ClinformaticsTM Data Mart for Multiplan claims database. The study found that patients experiencing hypoglycemia were significantly more likely to discontinue basal insulin therapy within a year, and they incurred higher healthcare costs, including increased hospitalizations and emergency department visits, compared to those without hypoglycemia. The study highlights the substantial healthcare burden associated with hypoglycemia in T2D patients undergoing insulin treatment, emphasizing the need for strategies to prevent and manage hypoglycemic events to improve patient outcomes and reduce healthcare costs. The findings underscore the importance of early intervention and careful monitoring during basal insulin initiation.